KR101769079B1 - 대사 장애를 치료 및 예방하기 위한 신규한 화합물 및 이를 포함하는 약학적 조성물 - Google Patents
대사 장애를 치료 및 예방하기 위한 신규한 화합물 및 이를 포함하는 약학적 조성물 Download PDFInfo
- Publication number
- KR101769079B1 KR101769079B1 KR1020127030621A KR20127030621A KR101769079B1 KR 101769079 B1 KR101769079 B1 KR 101769079B1 KR 1020127030621 A KR1020127030621 A KR 1020127030621A KR 20127030621 A KR20127030621 A KR 20127030621A KR 101769079 B1 KR101769079 B1 KR 101769079B1
- Authority
- KR
- South Korea
- Prior art keywords
- mmol
- methyloxy
- ethyl
- butyl
- tetrahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- VGGPAOIPWYDSDX-UHFFFAOYSA-N CCCCC(CCCC)(COS(O)(=O)=O)N Chemical compound CCCCC(CCCC)(COS(O)(=O)=O)N VGGPAOIPWYDSDX-UHFFFAOYSA-N 0.000 description 1
- NTSDKMSNIIXQCI-NQYPTXOGSA-N CCCC[C@@]1(CC)N[C@H](c2ccccc2)c(cc(c(CN[C@@H](CSSC[C@@H](C(O)=O)N)C(O)=O)c2)OC)c2SC1 Chemical compound CCCC[C@@]1(CC)N[C@H](c2ccccc2)c(cc(c(CN[C@@H](CSSC[C@@H](C(O)=O)N)C(O)=O)c2)OC)c2SC1 NTSDKMSNIIXQCI-NQYPTXOGSA-N 0.000 description 1
- VIVRTOOXGVMLDB-KAYWLYCHSA-N CCCC[C@](CC)(C1)N[C@H](c2ccccc2)c(cc(c(CCC(NCC(O)=O)=O)c2)OC)c2S1(=O)=O Chemical compound CCCC[C@](CC)(C1)N[C@H](c2ccccc2)c(cc(c(CCC(NCC(O)=O)=O)c2)OC)c2S1(=O)=O VIVRTOOXGVMLDB-KAYWLYCHSA-N 0.000 description 1
- NGDCKFGCBVQPPC-RSYUDSDASA-N CCCC[C@](CC)(C1)N[C@H](c2ccccc2)c(cc(c(CN[C@@H]([C@@H](C)O)C(O)O)c2)OC)c2S1(=O)=O Chemical compound CCCC[C@](CC)(C1)N[C@H](c2ccccc2)c(cc(c(CN[C@@H]([C@@H](C)O)C(O)O)c2)OC)c2S1(=O)=O NGDCKFGCBVQPPC-RSYUDSDASA-N 0.000 description 1
- LQROOPRQSMOGNQ-CLJLJLNGSA-N CCCC[C@](CC)(C1)N[C@H](c2ccccc2)c2cc(OC)c(CCCC(O)=O)cc2S1(=O)=O Chemical compound CCCC[C@](CC)(C1)N[C@H](c2ccccc2)c2cc(OC)c(CCCC(O)=O)cc2S1(=O)=O LQROOPRQSMOGNQ-CLJLJLNGSA-N 0.000 description 1
- GBEUTSGBUHICLW-LOYHVIPDSA-N CCCC[C@](CC)(C1)N[C@H](c2ccccc2)c2cc(OC)c(CNC(CNC(CC(O)=O)CC(O)=O)=O)cc2S1(=O)=O Chemical compound CCCC[C@](CC)(C1)N[C@H](c2ccccc2)c2cc(OC)c(CNC(CNC(CC(O)=O)CC(O)=O)=O)cc2S1(=O)=O GBEUTSGBUHICLW-LOYHVIPDSA-N 0.000 description 1
- KZYGGUUKJCPZHO-UHFFFAOYSA-N COC(C1(CNNCC2(CC2)C(OC)=O)CC1)=O Chemical compound COC(C1(CNNCC2(CC2)C(OC)=O)CC1)=O KZYGGUUKJCPZHO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/36—Seven-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6539—Five-membered rings
- C07F9/6541—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32821210P | 2010-04-27 | 2010-04-27 | |
| US61/328,212 | 2010-04-27 | ||
| US32922510P | 2010-04-29 | 2010-04-29 | |
| US61/329,225 | 2010-04-29 | ||
| PCT/US2011/034024 WO2011137135A1 (en) | 2010-04-27 | 2011-04-27 | Chemical compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20130060201A KR20130060201A (ko) | 2013-06-07 |
| KR101769079B1 true KR101769079B1 (ko) | 2017-08-30 |
Family
ID=44861895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020127030621A Active KR101769079B1 (ko) | 2010-04-27 | 2011-04-27 | 대사 장애를 치료 및 예방하기 위한 신규한 화합물 및 이를 포함하는 약학적 조성물 |
Country Status (39)
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3400944T (lt) | 2010-11-04 | 2020-09-25 | Albireo Ab | Ibat inhibitoriai, skirt kepenų ligų gydymui |
| JP2014527071A (ja) * | 2011-08-31 | 2014-10-09 | マリンクロッド エルエルシー | Ｈ−ホスホネートによるナノ粒子ｐｅｇの改変 |
| JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
| RU2015144632A (ru) | 2013-05-02 | 2017-06-07 | Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Терапевтические пептиды |
| KR102560954B1 (ko) | 2014-06-25 | 2023-07-31 | 이에이 파마 가부시키가이샤 | 고형 제제 및 그의 착색 방지 또는 착색 감소 방법 |
| CA2956833C (en) * | 2014-08-05 | 2022-08-30 | Glaxosmithkline Intellectual Property (No.2) Limited | Synthesis of benzothiazepines |
| KR101674806B1 (ko) * | 2014-10-20 | 2016-11-10 | 씨제이헬스케어 주식회사 | 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도 |
| EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
| WO2016126726A1 (en) | 2015-02-02 | 2016-08-11 | Forma Therapeutics, Inc. | Bicyclic [4,6,0] hydroxamic acids as hdac6 inhibitors |
| CN107801396B (zh) | 2015-02-02 | 2021-10-22 | 福马治疗股份有限公司 | 作为hdac抑制剂的3-芳基-4-酰氨基-二环[4,5,0]异羟肟酸 |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| EP3472131B1 (en) | 2016-06-17 | 2020-02-19 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors |
| CA3027725C (en) | 2016-06-27 | 2025-05-06 | Glaxosmithkline Intellectual Property (No.2) Limited | SYNTHESIS OF GSK23390672 BY EPOXY HYDROLASE RESOLUTION |
| JP2020530448A (ja) | 2017-08-09 | 2020-10-22 | アルビレオ・アクチボラグ | コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用 |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| ES2942443T3 (es) * | 2018-06-05 | 2023-06-01 | Albireo Ab | Compuestos de benzotia(di)azepina y su uso como moduladores de ácidos biliares |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| PE20210136A1 (es) | 2018-06-20 | 2021-01-21 | Albireo Ab | Formulacion farmaceutica de odevixibat |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| CA3127408A1 (en) | 2019-02-06 | 2020-08-13 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| SMT202300020T1 (it) | 2019-02-06 | 2023-03-17 | Albireo Ab | Composti di benzotiadiazepine e loro uso come modulatori degli acidi biliari |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| EP3923943B1 (en) | 2019-02-12 | 2024-07-31 | Mirum Pharmaceuticals, Inc. | Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency |
| JP7665620B2 (ja) | 2019-12-04 | 2025-04-21 | アルビレオ・アクチボラグ | ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| EP4069361B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| TWI877262B (zh) | 2019-12-04 | 2025-03-21 | 瑞典商艾爾比瑞歐公司 | 苯并噻氮呯化合物及其作為膽酸調節劑之用途 |
| ES2973549T3 (es) | 2019-12-04 | 2024-06-20 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como moduladores de los ácidos biliares |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| WO2021110884A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2021110885A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| WO2021110886A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| ES2972045T3 (es) | 2019-12-04 | 2024-06-10 | Albireo Ab | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar |
| PT4069360T (pt) | 2019-12-04 | 2024-03-06 | Albireo Ab | Compostos de benzotia(di)azepina e a sua utilização como moduladores de ácido biliar |
| WO2022029101A1 (en) | 2020-08-03 | 2022-02-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| ES3002777T3 (en) | 2020-08-03 | 2025-03-07 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US20230414634A1 (en) | 2020-10-20 | 2023-12-28 | Glaxosmithkline Intellectual Property (No.2) Limited | Methods for treating cholestatic pruritus |
| KR20230106651A (ko) | 2020-11-12 | 2023-07-13 | 알비레오 에이비 | 진행성 가족성 간내 담즙정체증(pfic)을 치료하기 위한 오데빅시바트 |
| CA3198216A1 (en) | 2020-12-04 | 2022-06-09 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| JP2024501814A (ja) * | 2020-12-23 | 2024-01-16 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッド | リネリキシバットの形態 |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| WO2023203248A1 (en) | 2022-04-22 | 2023-10-26 | Albireo Ab | Subcutaneous administration of an asbt inhibitor |
| CN119343140A (zh) | 2022-06-09 | 2025-01-21 | 阿尔比里奥公司 | 治疗肝炎 |
| KR20250029896A (ko) | 2022-07-05 | 2025-03-05 | 알비레오 에이비 | 벤조티아(디)아제핀 화합물 및 담즙산 조절제로서의 이의 용도 |
| US20240207286A1 (en) | 2022-12-09 | 2024-06-27 | Albireo Ab | Asbt inhibitors in the treatment of renal diseases |
| WO2024251739A1 (en) | 2023-06-06 | 2024-12-12 | Glaxosmithkline Intellectual Property (No.2) Limited | Novel use of an ileal bile acid transporter inhibitor for the treatment of pruritus |
| WO2025078973A1 (en) | 2023-10-09 | 2025-04-17 | Assia Chemical Industries Ltd. | Solid state forms of linerixibat and process for preparation thereof |
| WO2025146508A1 (en) | 2024-01-05 | 2025-07-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2025146507A1 (en) | 2024-01-05 | 2025-07-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996005188A1 (en) | 1994-08-10 | 1996-02-22 | The Wellcome Foundation Limited | Hypolipidemic 1,4-benzothiazepine-1,1-dioxides |
| US20040077625A1 (en) * | 2001-07-25 | 2004-04-22 | Tremont Samuel J. | Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake |
| WO2004076430A1 (en) * | 2003-02-25 | 2004-09-10 | Astrazeneca Ab | Benzothiazepine and benzothiepine derivatives |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2370015A (en) | 1933-07-24 | 1945-02-20 | Merck & Co Inc | Derivatives of tertiary amino aliphatic acids |
| GB9203347D0 (en) * | 1992-02-17 | 1992-04-01 | Wellcome Found | Hypolipidaemic compounds |
| IL108634A0 (en) | 1993-02-15 | 1994-05-30 | Wellcome Found | Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them |
| US6268392B1 (en) * | 1994-09-13 | 2001-07-31 | G. D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors |
| US20020183307A1 (en) | 2000-07-26 | 2002-12-05 | Tremont Samuel J. | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake |
| WO2002053548A1 (fr) * | 2000-12-27 | 2002-07-11 | Banyu Pharmaceutical Co.,Ltd. | Derives de la benzothiazepine |
| US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| CA2471639A1 (en) * | 2002-01-17 | 2003-07-31 | Pharmacia Corporation | Novel alkyl/aryl hydroxy or keto thiepines. |
| DE602004006831T2 (de) | 2003-01-09 | 2008-02-14 | Genentech, Inc., South San Francisco | Reinigung von polypeptiden |
| WO2006026754A2 (en) | 2004-09-03 | 2006-03-09 | Plexxikon, Inc. | Bicyclic heteroaryl pde4b inhibitors |
| WO2010062861A2 (en) * | 2008-11-26 | 2010-06-03 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of obesity and diabetes |
-
2011
- 2011-04-25 JO JOP/2011/0139A patent/JO3131B1/ar active
- 2011-04-26 AR ARP110101432A patent/AR081337A1/es active IP Right Grant
- 2011-04-26 UY UY0001033353A patent/UY33353A/es not_active Application Discontinuation
- 2011-04-27 CA CA2795543A patent/CA2795543C/en active Active
- 2011-04-27 SI SI201130920A patent/SI2563122T1/sl unknown
- 2011-04-27 MX MX2012012527A patent/MX2012012527A/es active IP Right Grant
- 2011-04-27 KR KR1020127030621A patent/KR101769079B1/ko active Active
- 2011-04-27 JP JP2013508174A patent/JP5702853B2/ja active Active
- 2011-04-27 MY MYPI2012004753A patent/MY162933A/en unknown
- 2011-04-27 EP EP11775513.2A patent/EP2563122B1/en active Active
- 2011-04-27 SG SG2012074860A patent/SG184812A1/en unknown
- 2011-04-27 UA UAA201211711A patent/UA110338C2/ru unknown
- 2011-04-27 ES ES11775513.2T patent/ES2588743T3/es active Active
- 2011-04-27 WO PCT/US2011/034024 patent/WO2011137135A1/en not_active Ceased
- 2011-04-27 NZ NZ602754A patent/NZ602754A/en unknown
- 2011-04-27 MA MA35373A patent/MA34235B1/fr unknown
- 2011-04-27 PL PL11775513.2T patent/PL2563122T3/pl unknown
- 2011-04-27 CN CN201180021342.6A patent/CN102858159B/zh active Active
- 2011-04-27 AU AU2011245393A patent/AU2011245393B2/en active Active
- 2011-04-27 BR BR112012026767A patent/BR112012026767B1/pt active IP Right Grant
- 2011-04-27 LT LTEP11775513.2T patent/LT2563122T/lt unknown
- 2011-04-27 HR HRP20161103TT patent/HRP20161103T1/hr unknown
- 2011-04-27 DK DK11775513.2T patent/DK2563122T3/en active
- 2011-04-27 EA EA201290909A patent/EA021753B1/ru not_active IP Right Cessation
- 2011-04-27 PE PE2012002082A patent/PE20130384A1/es active IP Right Grant
- 2011-04-27 HU HUE11775513A patent/HUE029480T2/en unknown
- 2011-04-27 ME MEP-2016-160A patent/ME02490B/me unknown
- 2011-04-27 RS RS20160709A patent/RS55079B1/sr unknown
- 2011-04-27 PH PH1/2012/502128A patent/PH12012502128B1/en unknown
- 2011-04-27 US US13/640,166 patent/US9040518B2/en active Active
- 2011-04-27 PT PT117755132T patent/PT2563122T/pt unknown
-
2012
- 2012-09-28 CO CO12170751A patent/CO6612267A2/es active IP Right Grant
- 2012-10-04 DO DO2012000263A patent/DOP2012000263A/es unknown
- 2012-10-11 IL IL222365A patent/IL222365A/en active IP Right Grant
- 2012-10-18 ZA ZA2012/07858A patent/ZA201207858B/en unknown
- 2012-10-26 CL CL2012003009A patent/CL2012003009A1/es unknown
- 2012-11-01 CR CR20120557A patent/CR20120557A/es unknown
-
2016
- 2016-08-24 CY CY20161100830T patent/CY1118187T1/el unknown
- 2016-08-29 SM SM201600293T patent/SMT201600293B/it unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996005188A1 (en) | 1994-08-10 | 1996-02-22 | The Wellcome Foundation Limited | Hypolipidemic 1,4-benzothiazepine-1,1-dioxides |
| US20040077625A1 (en) * | 2001-07-25 | 2004-04-22 | Tremont Samuel J. | Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake |
| WO2004076430A1 (en) * | 2003-02-25 | 2004-09-10 | Astrazeneca Ab | Benzothiazepine and benzothiepine derivatives |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101769079B1 (ko) | 대사 장애를 치료 및 예방하기 위한 신규한 화합물 및 이를 포함하는 약학적 조성물 | |
| AU2011245393A1 (en) | Chemical compounds | |
| CN108516958B (zh) | 稠环衍生物、其制备方法、中间体、药物组合物及应用 | |
| JP3304093B2 (ja) | 回腸の胆汁酸輸送及びタウロコール酸塩吸収の阻害活性を有する新規ベンゾチエピン類 | |
| US6740663B2 (en) | Mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake | |
| JP2001526627A (ja) | 回腸胆汁酸輸送及びタウロコール酸塩吸収の阻害剤としての活性を有する新規ベンゾチエピン類 | |
| JP2002519418A (ja) | 回腸胆汁酸運搬及びラウコロール酸塩摂取の阻害剤としての活性を有するベンゾチエピン類 | |
| EP2078022B1 (en) | Spiro benzazepines used as vasopressin antagonists | |
| JP2009519248A (ja) | 抗糖尿病剤としてのチアジアゾール誘導体 | |
| WO1992012148A1 (en) | 1,4-benzothiazepine derivative | |
| CN101133037B (zh) | 六元杂环化合物及其用途 | |
| TWI893663B (zh) | 作為乙醇酸氧化酶抑制劑之雜環甲酸化合物 | |
| JPH0460597B2 (OSRAM) | ||
| WO1998003503A1 (fr) | Derives de n-benzenesulfonyl-l-proline en tant qu'agonistes de la bradykinine b2 | |
| AU778810B2 (en) | Nonpeptide substituted benzothiazepines as vasopressin antagonists | |
| EA008797B1 (ru) | Новые соединения бензотиазина и бензотиадиазина, способ их получения и фармацевтические композиции, которые их содержат | |
| FR2941947A1 (fr) | Derives de 3-benzofuranyl-indol-2-one subtitues en 3, leur preparation et leur application en therapeutique | |
| HK1175650B (en) | Chemical compounds | |
| CA2375268A1 (en) | Indoloazepines as vasopressin receptor antagonists | |
| KR20040072730A (ko) | 글리코겐 인산화효소 억제제의 제조를 위한 중간체 | |
| CN117945945A (zh) | 一种gpr139受体激动剂、其制备方法及其应用 | |
| WO2020207263A1 (zh) | 苯并咪唑化合物、其制备方法及其用途 | |
| JPH05201993A (ja) | メイラード反応阻害剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 6 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 7 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 8 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 9 |